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STUDY IMPORTANCE:  
• Intra-ventromedial hypothalamic melanocortin receptor activation increases physical 
activity and energy expenditure 
• Here, we demonstrate that this response is enhanced in inherently lean rats 
• Intrinsic differences in brain melanocortins and sympathetic outflow to muscle may 
underlie the elevated activity energy expenditure seen in leanness 
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ABSTRACT  
Objective 
Activity thermogenesis and energy expenditure (EE) are elevated in intrinsically lean rats (high-
capacity runners, HCR), and are also stimulated by melanocortin receptor activation in the 
ventromedial hypothalamus (VMH). Here, we determined if HCR are more responsive to central 
modulation of activity EE compared to low-capacity runners (LCR). 
Methods 
HCR and LCR rats received intra-VMH microinjections of Melanotan II (MTII), a mixed 
melanocortin receptor agonist. Changes in EE, respiratory exchange ratio (RER), activity EE, 
muscle heat, norepinephrine turnover (NETO), and muscle energetic modulators were compared. 
Results  
HCR were significantly more responsive to intra-VMH MTII-induced changes in EE, activity 
EE, NETO to some muscle subgroups, and muscle mRNA expression of some energetic 
modulators. Though HCR had high muscle activity thermogenesis, limited MTII-induced 
modulation of muscle thermogenesis during activity was seen in LCR only.  
Conclusions 
An inherently lean, high-capacity rat phenotype showed elevated response to central 
melanocortin stimulation of activity EE and use of fat as fuel. This may be driven by sympathetic 
outflow to skeletal muscle, which was elevated after MTII. Central melanocortin receptor 
activation also altered skeletal muscle energetic modulators in a manner consistent with elevated 
EE and lowered RER.  
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INTRODUCTION  
Genetic and environmental factors interact to influence energy balance. One characteristic that 
differs with leanness is physical activity, a heritable trait that varies widely between individuals in 
both humans and rodents
1,2,3
. Across species, intrinsic aerobic capacity predicts high physical 
activity, health, longevity, and a favorable metabolic profile
4,5,6,7,8,9,10,11
. Rats selectively bred as 
high capacity runners (HCR) are more physically active than their counterparts selectively bred 
as low capacity runners (LCR). LCR are prone to weight gain, obesity, and cardiovascular 
disorders
6,12
, and HCR have a low adiposity, high activity (independent of differences in body 
weight
13
), and high energy expenditure (EE) relative to body size
13
. The high EE seen in HCR is 
predominantly due to heightened non-resting EE
13
, which persists even during controlled 
activity, indicating low economy of activity—more kcal used for the same workload—in the 
HCR
12,13
. This implicates skeletal muscle energetic and thermogenic mechanisms, which may 
stem from the enhanced sympathetic drive observed in HCR
13
.  
 
The elevated activity, EE, SNS drive, and muscle expression of energetic mediators 
characteristic of HCR are also modulated by central melanocortin receptors
14,15,16
, suggesting a 
melanocortinergic mechanism for the muscle energetic phenotype of HCR. Like brain 
melanocortins, the ventromedial hypothalamus (VMH) plays an important role in fuel 
allocation
15,16,17,18
. Activation of VMH melanocortin receptors using a non-specific agonist 
Melanotan II (MTII) increases EE and physical activity, and decreases respiratory exchange ratio 
(RER), switching fuel preference to fats; it lowers fuel economy during activity where ‘wasted’ 
calories are dissipated as heat
14
. HCR and LCR respond differently to central melanocortins
19,20
, 
a system known to modulate sympathetic drive
15,16,21
. Here, we examine how VMH melanocortin 
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receptors alter activity-related EE, heat dissipation, SNS drive, and molecular mediators of 
energy homeostasis in lean (HCR) and obesity-prone (LCR) rats, predicting that increased EE 
and thermogenesis will be reflected in augmented activation at each level of this brain-muscle 
pathway. 
 
METHODS   
Adult male HCR/LCR rats (N=104, 52/group, generation 32 and 34) from the University of 
Michigan were individually housed on a 12:12 light:dark cycle (lights on at 0700 EST) and 
received food (5P00 MRH 3000) and water ad libitum. All studies were approved by the Kent 
State University IACUC. 
 
Stereotaxic surgery and transponder implantation 
Stereotaxic surgeries were performed to chronically implant guide cannulae aimed at the VMH
14
. 
Briefly, rats (total N=86 for cannulation) were anesthetized using isoflurane and mounted on a 
stereotaxic apparatus using atraumatic ear bars. The VMH was targeted using the coordinates: 
anterior-posterior, -2.5mm; medial-lateral, +0.5mm; dorsal-ventral, -6mm (from dura), and an 
injection needle with 3mm projection (final dorsal-ventral, -9mm from dura). After completion 
of the study, rats with guide cannulae within 250µm of the VMH (N=74 accurate placements) 
were used for data analysis as shown in our previous studies
14,20
. In 24 male HCR/LCR 
(12/group) during stereotaxic surgery, sterile IPTT-300 temperature transponders (Bio Medic 
Data Systems, Inc.) were implanted on interscapular brown adipose tissue (BAT) and adjacent to 
gastrocnemius muscle bilaterally.  
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Body composition and energy expenditure 
Body composition was measured using an EchoMRI-700 (EchoMRI, Houston, TX) to determine 
the fat and lean mass (in grams) of each rat the day before experiments. This did not interfere 
with transponder function. After 24-48hrs of acclimation in testing cages, EE and physical 
activity were measured using small-animal indirect calorimetry (4-chamber Oxymax FAST 
system, Columbus Instruments, Columbus, OH) at thermoneutral conditions, as previously 
reported
13,14
. Rats were injected either with the nonspecific melanocortin receptor agonist MTII 
(20pmoles/200nl) or vehicle (aCSF, 200nl)
14
. The first 15 min of data was not included in the 
analysis. EE data (VO2, VCO2, RER, kcal/hr) were averaged, and physical activity data were 
expressed as mean beam breaks/minute. In all EE and thermogenesis studies described here, all 
rats received counterbalanced vehicle and MTII injections separated by at least four days, with 
each rat acting as its own control thereby nullifying the effect of body weight and 
composition
22,23
. For EE, analysis of covariate was used to account for differences in body 
composition. 
 
To assess locomotor efficiency, physical-activity EE was measured using gas exchange during a 
treadmill activity test; MTII-induced physical activity precluded accurate measurement of resting 
EE. At least one day after a 15-min treadmill acclimation period, rats were placed in the 
treadmill after injections of either MTII (20pmoles/200nl) or vehicle (aCSF) and allowed to 
acclimate without food for 2 hrs. Rats then walked on the treadmill at 7 m/min for 30 min while 
activity-EE data were collected every 10 sec. All EE data from both studies were analyzed using 
2x2 mixed ANOVA using SPSS, with ANOVA significance set at p < 0.05 unless otherwise 
stated.   
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Muscle temperature 
Skeletal muscle and BAT heat dissipation were measured every 15 min for 4 hrs after intra-
VMH MTII or vehicle microinjection, with BAT thermogenesis as a positive control. In a 
separate experiment, rats received microinjections of either MTII or vehicle 1.5 hrs prior to 
measurement of skeletal muscle heat dissipation during controlled physical activity on a 
treadmill. Gastrocnemius temperatures in each leg were recorded at baseline (before injecting 
and immediately before treadmill walking) and at set intervals during a 35-min, 5-level graded 
treadmill test as reported previously
13,14
. Data from each study were analyzed using 3-way 
ANOVAs. 
 
Norepinephrine turnover (NETO) 
Norepinephrine (NE) turnover (NETO) was used to assess sympathetic drive to peripheral tissues 
including liver, heart, BAT, skeletal muscle (including quadriceps, lateral and medial 
gastrocnemius, EDL, and soleus), and WAT depots (mesenteric (MWAT), gluteal (GWAT), 
retroperitoneal (RWAT), inguinal (IWAT), and epididymal WAT (EWAT)) in HCR and LCR. 
NETO was measured using α-methyl-p-tyrosine (aMPT in saline vehicle) as previously 
reported
24,25
. HCR and LCR were divided into 3 groups (aMPT/MTII, aMPT/aCSF-vehicle, 
control; n=8/group). On the day of the study, food was removed and assigned rats were given 
aMPT injections (125 mg aMPT/kg body weight; 25 mg/ml) 2 and 4 hrs before tissue collection; 
30 minutes after the first aMPT injection, rats received intra-VMH MTII or vehicle. All rats were 
euthanized by rapid decapitation between 1200 and 1500 EST (5-8 hrs after lights-on), 4 hours 
after the first aMPT injection. Tissues were rapidly dissected and snap-frozen in liquid nitrogen. 
Catecholamines were isolated from homogenized tissue and measured using HPLC, as 
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previously described
13,14,24,25
. NETO was calculated:  
k = (lg[NE]0 – lg[NE]4)/(0.434 x 4)  
K = k[NE]0  
k is the constant rate of NE efflux (also known as fractional turnover rate),  
[NE]0 is the initial NE concentration or from 0-hr group (control),  
[NE]4 is the final NE concentration or from 4-hr group (aMPT-MTII/ aMPT-vehicle), and  
K = NETO. 
Differences in tissue NETO between intra-VMH MTII-microinjected and vehicle-microinjected 
rats were calculated with respect to control-group rats; NETO/gram tissue/hour was compared 
using a 2x2 mixed ANOVA. 
 
mRNA and protein expression 
Skeletal muscle (gastrocnemius and quadriceps), liver, MWAT, and BAT were collected from 
HCR/LCR rats (N=32, 16/group) 4hrs after intra-VMH microinjection of either MTII or vehicle 
(N=8/treatment). Tissue samples were homogenized and total mRNA extracted as previously 
reported
13,14
, and compared to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) using the 
comparative Ct method (∆Ct). See Supplementary Material for list of primers. Protein was 
isolated from tissue homogenate
13,14
 and compared using Western blots. Primary and secondary 
antibodies (see Supplementary Material) were diluted in blocking buffer according to 
manufacturer instructions and developed using a chemiluminescence detector using an 
Amersham kit (GE Healthcare, UK). Data are expressed as a percent expression using samples 
from vehicle-treated HCR rats as the reference value (defined as 100%) relative to GAPDH (for 
mRNA) or actin (for protein), and were analyzed using 2x2 mixed ANOVA. As we were 
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specifically interested in the magnitude of effect of MTII in HCR vs. LCR, we used planned (a 
priori) comparisons using t-tests with a Bonferroni correction (two t-tests with p<0.025). 
 
RESULTS  
For body weight and composition, LCR were consistently larger with more fat and lean mass 
than HCR. Some slight but significant differences were found between treatments (Table S1). 
Statistical results are listed in Tables S2-S16, with data expressed as mean ± SEM. 
 
EE in HCR was more responsive to intra-VMH MTII  
As shown in Figure 1A-D, intra-VMH MTII significantly increased EE, VO2, and physical 
activity (horizontal and ambulatory), with a significantly greater response in HCR (significant 
interaction), and lowered RER in both HCR and LCR. HCR had higher activity (all dimensions), 
VO2, and VCO2. MTII also increased treadmill-activity EE and VO2 (Figure 1E-H); MTII 
decreased RER more in LCR than HCR (Figure 1G). HCR showed a greater MTII-induced 
increase in treadmill-activity EE (Figure 1H). There were significant interactions between 
treatment and HCR/LCR for free-moving EE and treadmill-activity EE, using either body weight 
or lean mass as covariates. Treadmill-walking EE showed main effects where HCR had lower 
EE and RER, and a trend toward higher treadmill VO2.  
 
Muscle heat dissipation 
As described in the Supplementary Material, during resting, compared to vehicle, MTII induced 
an increase in BAT temperature, and the change in temperature from baseline was significantly 
higher after MTII treatment (compared to vehicle) between 30min and 120min after injection 
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(Figure S1). There were no significant differences in BAT response to MTII between HCR and 
LCR. Compared to vehicle, intra-VMH MTII did not significantly increase gastrocnemius 
muscle temperatures or elevation relative to baseline (Figure S2). Compared to vehicle 
injections, MTII injections induced higher treadmill activity-associated gastrocnemius 
temperatures in LCR (Figure 2A, B). Consistent with previous findings
13
, lean HCR had a 
greater change in treadmill locomotion-induced skeletal muscle heat dissipation during treadmill 
locomotion under both vehicle- and MTII-injected conditions compared to obesity-prone LCR 
(Figure 2B).  
 
Intra-VMH MTII microinjection differentially elevated sympathetic drive to metabolic 
tissues in lean vs. obesity-prone rats  
Compared to vehicle, intra-VMH MTII induced a significant increase in SNS drive to skeletal 
muscle of both lean HCR and obesity-prone LCR, although HCR were significantly more 
affected (significant interaction) than LCR in soleus, quadriceps, and lateral gastrocnemius 
(Figure 3). Intra-VMH MTII also induced a significant increase in SNS drive to all WAT depots 
examined, BAT, heart, and liver (Figure 3, Table 1). MTII-induced NETO was greater in HCR 
than in LCR (significant interaction) for MWAT, GWAT, and IWAT, as well as for BAT and 
liver (Table 1). In heart, both baseline and MTII-induced NETO was greater in LCR than HCR, 
with a significant interaction where LCR showed a greater response to MTII (Figure 3F). 
Compared to vehicle-treated LCR, vehicle-treated HCR had higher NETO in skeletal muscle, 
BAT, and MWAT, consistent with previous baseline findings for skeletal muscle and BAT
13
.  
 
Intra-VMH MTII elevated expression of mRNA of mediators of energy expenditure 
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Levels of mRNA expression of potential molecular mediators of energy balance are shown in 
Table 2 and Figure 3. Compared to vehicle-treated HCR, gastrocnemius muscle of intra-VMH 
MTII-treated HCR had significantly higher mRNA expression of UCP2, UCP3, PGC-1α, 
PPARα, PPARδ, PPARγ, SERCA1, SERCA2, and β2 AR, and a significant decrease in Kir6.2 
(Figure 4A). Gastrocnemius showed a significantly higher expression of UCP2, UCP3, PPARα, 
PPARγ, and SERCA2 in MTII-treated LCR than vehicle-treated LCR. In quadriceps, MTII- and 
vehicle-microinjected HCR differed in mRNA expression (MTII>vehicle, within HCR) of 
UCP2, UCP3, PPARα, PPARδ, SERCA1, and SERCA2 (Figure 4B). MTII-treated LCR 
quadriceps showed significantly higher mRNA expression of UCP2 and UCP3 (Figure 4B) 
compared to vehicle-treated LCR quadriceps.  
 
Compared to vehicle-treated rats, HCR but not LCR with intra-VMH MTII microinjections had 
significantly elevated mRNA expression of UCP1, PGC-1α, PPARδ, PPARγ, and PPARα in 
BAT (Table 2). Compared to vehicle, intra-VMH MTII also induced a significant increase in 
mRNA expression of PPARγ, PPARα, and PPARδ in WAT of intra-VMH MTII treated HCR 
where LCR showed MTII-induced increase in mRNA expression of PPARα and PPARδ in 
WAT. In liver, intra-VMH MTII-treated HCR showed significantly higher mRNA expression of 
UCP2, PPARα, PPARδ, PPARγ, and PGC-1α compared to vehicle-treated HCR. In LCR liver, 
MTII- and vehicle-treated rats significantly differed in mRNA expression of PPARα, PPARδ, 
PPARγ, and PGC-1α.  
 
As shown in Table 3 and Figure S3, protein expression of mediators of EE did not consistently 
change in accordance with mRNA expression. In quadriceps, MTII-treated HCR only showed 
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trends in pAMPK, pACC, PPARγ, and SERCA1. No significant differences or trends were found 
in protein expression with intra-VMH MTII in LCR. In gastrocnemius, intra-VMH MTII-
microinjected HCR showed significantly higher expression of PGC-1α, pAMPK, and pACC 
compared to vehicle-treated HCR, with trends in other mediators; no significant differences were 
found in LCR (Figure S3). 
 
As shown in Table 3 and Figure S3, in BAT of HCR, MTII-treated rats showed significantly 
higher UCP1, PGC-1α, pAMPK, and pACC. No significant differences were observed with 
MTII in LCR. No significant differences were observed with MTII in WAT except in pAMPK in 
MTII-treated HCR compared to vehicle-treated HCR. In liver, MTII-microinjected HCR showed 
significantly more pACC and pAMPK; no significant differences were observed in LCR.  
 
DISCUSSION 
Phenotypic leanness associated with high intrinsic aerobic capacity in rats is coupled with 
elevated total EE, and the predominant source of this is activity-related EE stemming from high 
daily physical activity along with low economy of activity in these rats
12,13
. This low muscle 
work efficiency suggests wasting of calories to a greater extent in HCR than LCR, potentially 
modulated by enhanced sympathetic drive and altered expression of molecular mediators of 
energy conservation and expenditure observed in HCR
13
. These phenotypic differences were 
similar to those seen in response to intra-VMH melanocortin receptor activation
14
, suggesting an 
elevated response of the melanocortinergic VMH-SNS-muscle axis in the lean HCR. Here, we 
identified a phenotype-linked increase in EE, physical activity, activity-associated EE, and VO2 
after site-specific activation of central melanocortin receptors. Many of these energetic changes 
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were amplified in lean HCR compared to obesity-prone LCR; for example, VMH melanocortin 
receptor activation had a greater impact on EE and VO2 in HCR (Figure 1), even taking into 
account differences in body weight and composition. The melanocortin receptor stimulation of 
EE during low- and moderate-intensity physical activity implicates mechanistic changes 
impacting muscle work efficiency, particularly in the lean HCR. This stems in part from 
enhanced central activation of SNS outflow to muscle. Elevated functioning of this brain-SNS-
muscle axis in the high-capacity phenotype may be an important factor promoting aerobic 
capacity and potentially leanness. 
 
Some thermogenic changes accompanied the MTII-induced increase in EE. BAT thermogenesis 
showed a short-term increase in freely moving MTII-treated rats (Figure S1). MTII enhanced 
treadmill-walking gastrocnemius muscle temperature, but contrary to expectation, obesity-prone 
LCR showed a greater response in their muscle heat dissipation during activity, approaching the 
level of vehicle-treated HCR (Figure 2). Prior reports indicate that during activity, EE and 
muscle thermogenesis rise alongside each other, are similarly enhanced by central stimuli
14
, and 
are suppressed in concert after weight loss
26
. Muscle thermogenesis plateaus at relatively low 
levels of exertion
13,14,26,27
. This implies that, mechanistically, heat dissipation does not fully 
correspond to calorie use in muscle, particularly at higher workloads. Given the high muscle 
activity thermogenesis seen in HCR
13
, central MTII may enhance EE without being reflected in 
further incremental increases in muscle temperature (i.e., subject to a ceiling effect). Our data 
also suggest that melanocortin stimulation can be used to enhance or normalize activity 
thermogenesis even in the obesity prone. 
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Activity thermogenesis and skeletal muscle metabolism are important in maintaining leanness
28
, 
and this may be driven in part through central modulation. Evidence implicates a pathway 
through which the VMH and central melanocortin system integrate central and peripheral 
metabolic cues to meet muscle energy and glucose needs
15,16,29
 though modulation of the 
SNS
16,30
. Here, we found that activation of VMH melanocortin receptors increased sympathetic 
outflow to peripheral metabolic systems in both HCR and LCR (Figure 3; Table 1). Moreover, in 
some muscle subgroups, NETO was significantly more enhanced by MTII in HCR compared to 
obesity-prone LCR. Differences in central autonomic regulation could therefore contribute to the 
overall higher SNS drive seen in the lean HCR
13
. The exception was the heart, where the MTII-
induced increase in sympathetic outflow was higher in the LCR, and LCR showed higher NETO 
both with and without central melanocortin receptor stimulation (Figure 3). This corresponds 
with evidence that HCR are protected against hypertension
6
 and with the role of melanocortin 
peptides and receptors in sympathetically driven hypertension and against the hypertensive 
effects of MTII
21,31,32
. The enhanced responsiveness of SNS outflow to muscle in HCR supports 
the idea that the amplified metabolic response to central melanocortins in HCR are due in part to 
higher SNS stimulation of muscle. This, along with muscle response to SNS signaling
33
, may 
underlie the phenotypic differences in fuel economy and the associated changes in cellular 
energy mediators in the periphery.  
 
Overall, these findings affirmed our previous identification of phenotype-dependent differences 
in HCR and LCR
13
 as well as muscle response to central melanocortin receptor activation
14
. 
Central melanocortin activation was effective in modulating mRNA expression in BAT and liver 
in both HCR and LCR (Figure 4, Table 2); here, we focus primarily on muscle, specifically on 
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mediators of thermogenesis, fatty acid metabolism, and energy conservation. Potential 
thermogenic mediators SERCA1 & 2 and UCP2 & 3 showed induced mRNA expression in 
quadriceps and oxidative gastrocnemius muscle with central melanocortin stimulation, with 
some elevation seen in HCR and not LCR (gastrocnemius SERCA1, quadriceps SERCA 1 & 2; 
Table 3). Conversely, mRNA expression of MED1 and components of ATP-gated K
+
 channels 
were higher in LCR muscle, potentially contributing to their overall lower muscle temperatures
35
 
and their energy conservation. Similar to previous reports
13,34
, central melanocortin stimulation 
induced mRNA expression of PGC-1α, PPARα, PPARγ, and PPARδ in oxidative gastrocnemius 
muscle, and PPARα, PPARδ in quadriceps, with many of these significant in HCR but not LCR 
(Figure 4). These changes may be responsible for the central melanocortin receptor-induced 
increase in EE and decrease in RER. While the 4-hr time course of the study was optimal to 
detect increases in mRNA expression, it likely obscured detection of suppressive effects of 
central MTII beyond one instance (Kir6.2 in HCR gastrocnemius; Figure 4) and some statistical 
trends (PPARα, pAMPK, PPARγ and pACC; Table 3). Also, the time course did not allow for 
adequate time for detection of altered protein expression. Most of the changes identified were 
phosphorylation related and did not require translation. The expression of the activated form of 
AMPK (pAMPK) may underlie the ability of central MTII to upregulate fatty acid oxidation and 
reduce RER through its regulation of ACC and CPT1
36
. Lastly, both mRNA and protein 
expression reinforced our previous findings
13
 showing baseline differences between HCR and 
LCR reflecting the observed phenotype-dependent differences in activity-related EE, RER, and 
muscle energy use. Taken together with the MTII-induced changes demonstrated here and the 
proposed melanocortin-activated VMH-SNS-muscle pathway, this suggests phenotypic 
differences in myocyte responsiveness to adrenergic stimuli, consistent with the findings of 
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Lessard et al., 2009
33
. 
 
Altogether, our data demonstrate that melanocortin receptors in the VMH activate SNS outflow, 
increasing sympathetic drive to skeletal muscle, modulate fuel allocation and use through 
differential activation of molecular mediators of energy homeostasis, and increase EE while 
lowering fuel economy of activity. We have also demonstrated that functioning of this axis is 
heightened at every level in HCR compared to LCR—activation of melanocortin receptors in the 
VMH increases energy use in peripheral tissues including muscle, with a stronger effect in the 
high-capacity phenotype
13,14
. It is likely that muscle fuel uptake and utilization is modulated 
through the SNS, affecting skeletal muscle or other metabolically active tissues. The central 
melanocortin system, differentially expressed in the lean HCR and obese LCR, is known to 
impact muscle lipid mobilization and glucose uptake in the periphery via the SNS
15,17,19,20,37,38
. 
These findings support the importance of central modulation of SNS outflow to muscle in 
modulating activity EE, and suggest that differences in this pathway are linked to a high-aerobic 
capacity phenotype that shows obesity resistance. We speculate that running capacity, leanness, 
and skeletal muscle energy use and thermogenesis are coupled mechanistically. These results 
implicate this pathway as a potential mechanism underlying high-endurance-associated low 
economy of activity and leanness, and may help identify potential mediators that can be targeted 
to alter energy balance equation towards negative energy balance. 
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FIGURE LEGENDS 
Figure 1: High-capacity runners (HCR) were more responsive to the ability of intra-
ventromedial hypothalamic (VMH) melanocortin receptor activation to enhance activity-
related energy expenditure (EE). Low-capacity runners (LCR) and HCR were given intra-
VMH microinjections of the mixed melanocortin receptor agonist Melanotan II (MTII; gray 
bars) or vehicle (Veh; black bars). Over 4 hours, with a significant interaction where HCR 
responded more than LCR, intra-VMH MTII significantly increased free-moving EE (A), VO2 
(B), and physical activity (D), while decreasing respiratory exchange ratio (RER) similarly in 
HCR and LCR (C). (E-H) Intra-VMH MTII also induced changes in EE and RER in rats walking 
on a treadmill at 7 meters/min for 30 min. MTII increased activity-associated EE (E) and VO2 
(F), and decreased RER (G) in HCR and LCR. HCR showed lower overall walking-induced 
RER, while intra-VMH MTII produced a larger RER decrease in LCR than HCR (G), whereas 
HCR were more responsive to MTII-induced enhancement of activity EE (H). *within group, 
MTII treatment significantly different from veh; **HCR significantly different from LCR within 
treatment; p<0.05. (N=10) 
 
Figure 2: (A) Low and moderate intensity treadmill activity increased skeletal muscle 
(gastrocnemius) temperature in high-capacity runners (HCR; circles) and low-capacity runners 
(LCR; triangles) after intra-ventromedial hypothalamic (VMH) microinjections of the mixed 
melanocortin receptor agonist Melanotan II (MTII; open symbols) or vehicle (Veh; filled 
symbols). (B) Walking-induced increases in muscle temperature from baseline were significantly 
higher in HCR, whereas intra-VMH MTII significantly increased activity-associated muscle heat 
dissipation in LCR but not HCR. *LCR, MTII treatment significantly different from Veh; ** 
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HCR > LCR, main effect (A) and difference at baseline (B); p<0.05. (N=10/HCR, 6/LCR) 
 
Figure 3: Norepinephrine turnover (NETO) showed differences in sympathetic drive in high- 
and low-capacity runners (HCR. LCR) after intra-ventromedial hypothalamic (VMH) 
microinjections of the mixed melanocortin receptor agonist Melanotan II (MTII; gray bars) or 
vehicle (Veh; black bars). Intra-VMH MTII significantly increased NETO in skeletal muscle 
including (A) medial gastrocnemius, (B) lateral gastrocnemius, (C) quadriceps, (D) soleus, and 
(E) extensor digitorum longus (EDL); HCR showed significantly higher NETO in each of these 
muscle groups, and also had significantly greater MTII-induced NETO in lateral gastrocnemius, 
quadriceps, and soleus (line x treatment interaction). (F) Intra-VMH MTII also increased NETO 
in heart, but here the MTII-induced increase was greater in LCR than HCR. *within group, MTII 
treatment significantly different from veh; **HCR significantly different from LCR within 
treatment; p<0.05. (N=7/HCR, 8/LCR) 
 
Figure 4: Intra-ventromedial hypothalamic (VMH) microinjections of the Melanotan II (MTII) 
altered mRNA expression of energetic mediators in skeletal muscle (A: medial gastrocnemius; 
B: quadriceps) in high-and low-capacity runners (HCR, LCR). Beta2: β2 adrenergic receptor; 
UCP2 and 3: uncoupling protein 2 and 3; PPARa, d, and g: peroxisome proliferator-activated 
receptor α, δ, and γ; SERCA 1 and 2: sarco/endoplasmic reticulum ATPase 1 and 2; Kir6.1 and 
6.1: subunits of the ATP-gated K
+
 channel, Med1: mediator of RNA polymerase II transcription 
subunit 1. HCR-MTII ≠ LCR-MTII in all cases. *within group, MTII treatment significantly 
different from veh; p<0.05. (N=8/group) 
 
Page 20 of 56
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
21 
 
REFERENCES 
1. Joosen AM, Gielen M, Vlietinck R, Westerterp KR. Genetic analysis of physical activity 
in twins. Am J Clin Nutr 2005;82(6):1253-1259. 
2. Levine JA, Kotz CM. NEAT--non-exercise activity thermogenesis--egocentric & 
geocentric environmental factors vs. biological regulation. Acta Physiol Scand, 
2005;184(4):309-318. 
3. Levine JA, Lanningham-Foster LM, McCrady SK, et al. Interindividual variation in 
posture allocation: possible role in human obesity. Science 2005;307(5709):584-586. 
4. Aspenes ST, Nilsen TI, Skaug EA, Bertheussen GF, Ellingsen O, Vatten L, Wisloff U. 
Peak oxygen uptake and cardiovascular risk factors in 4631 healthy women and men. 
Med Sci Sports Exerc 2011;43(8):1465-1473.  
5. Bray MS. Genomics, genes, and environmental interaction: the role of exercise. J Appl 
Physiol 2000;88(2):788-792. 
6. Koch LG, Britton SL, Wisloff U. A rat model system to study complex disease risks, 
fitness, aging, and longevity. Trends Cardiovasc Med 2012;22(2):29-34. 
7. Kodama S, Saito K, Tanaka S, Maki M, et al. Cardiorespiratory fitness as a quantitative 
predictor of all-cause mortality and cardiovascular events in healthy men and women: a 
meta-analysis. JAMA 2009;301(19):2024-2035.  
8. Novak CM, Escande C, Gerber SM, et al. Endurance capacity, not body size, determines 
physical activity levels: role of skeletal muscle PEPCK. PLoSONE 2009;4(e5869). 
9. Zhan WZ, Swallow JG, Garland T Jr., Proctor DN, Carter PA, Sieck GC. Effects of 
genetic selection and voluntary activity on the medial gastrocnemius muscle in house 
mice. J Appl Physiol 1999;87(6):2326-2333. 
Page 21 of 56
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
22 
10. Kokkinos P, Myers J, Kokkinos JP, et al. Exercise capacity and mortality in black and 
white men. Circulation 2008;117:614-622. 
11. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and 
mortality among men referred for exercise testing. N Engl J Med 2002;346:793-801. 
12. Novak CM, Escande C, Burghardt PR, et al. Spontaneous activity, economy of activity, 
and resistance to diet-induced obesity in rats bred for high intrinsic aerobic capacity. 
Horm Behav 2010;58(3):355-367. 
13. Gavini CK, Mukherjee S, Shukla C, Britton SL, Koch, LG, Shi H, Novak CM. Leanness 
and Heightened Non-Resting Energy Expenditure: Role of Skeletal Muscle Activity 
Thermogenesis. Am J Physiol Endocrinol Metab 2014;306(6):E635-47. 
14. Gavini CK, Jones WC II, Novak CM. Ventromedial hypothalamic melanocortin receptor 
activ tion: regulation of activity energy expenditure and skeletal muscle thermogenesis. 
J Physiol 2016;594:5285–5301. 
15. Toda C, Shiuchi T, Lee S, et al. Distinct effects of leptin and a melanocortin receptor 
agonist injected into medial hypothalamic nuclei on glucose uptake in peripheral tissues. 
Diabetes 2009; 58:2757-65. 
16. Shiuchi T, Haque MS, Okamoto S, et al. Hypothalamic orexin stimulates feeding-
associated glucose utilization in skeletal muscle via sympathetic nervous system. Cell 
Metab 2009;10:466–480. 
17. Tanaka T, Masuzaki H, Yasue S, et al. Central melanocortin signaling restores skeletal 
muscle AMP-activated protein kinase phosphorylation in mice fed a high-fat diet. Cell 
Metab 2007;5:395-402. 
18. Miyaki T, Fujikawa T, Kitaoka R, Hirano N, Matsumura S, Fushiki T, Inoue K. 
Page 22 of 56
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
23 
Noradrenergic projections to the ventromedial hypothalamus regulate fat metabolism 
during endurance exercise. Neuroscience 2011;190:239-50. 
19. Shukla C, Britton SL, Koch LG, Novak CM. Region-specific differences in brain 
melanocortin receptors in rats of the lean phenotype. Neuroreport 2012;23:596-600. 
20. Shukla C, Koch LG, Britton SL, Cai M, Hruby VJ, Bednarek M, Novak CM . 
Contribution of regional brain melanocortin receptor subtypes to elevated activity energy 
expenditure in lean, active rats. Neuroscience 2015;310:252-67. 
21. Rahmouni K, Haynes WG, Morgan DA, Mark AL. Role of melanocortin-4 receptors in 
mediating renal sympathoactivation to leptin and insulin. J. Neurosci 2003;23:5998–
6004. 
22. Schoeller DA, Jefford G. Determinants of the energy costs of light activities: inferences 
for interpreting doubly labeled water data. Int J Obes Relat Metab Disord 2002;26 (1):97-
101. 
23. Tschöp MH, Speakman JR, Arch JR, et al. A guide to analysis of mouse energy 
metabolism. Nat. Methods 2012;9:57–63. 
24. Shi H, Bowers RR, Bartness TJ. Norepinephrine turnover in brown and white adipose 
tissue after partial lipectomy. Physiol Behav 2004;81:535–42.  
25. Vaughan CH, Shrestha YB, Bartness TJ. Characterization of a novel melanocortin 
receptor-containing node in the SNS outflow circuitry to brown adipose tissue involved 
in thermogenesis. Brain Res 2011;1411:17-27. 
26. Almundarij TI, Gavini CK, Novak CM. Suppressed sympathetic outflow to skeletal 
muscle, muscle thermogenesis, and activity energy expenditure with calorie restriction. 
Physiol Rep. 2017 Feb;5(4). pii:e13171. 
Page 23 of 56
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
24 
27. Yoo Y, LaPradd M, Kline H, et al. 
 
Exercise activates compensatory thermoregulatory 
reaction in rats: a modeling study. J Appl Physiol. 2015;119(12):1400-10. 
28. Jensen MD. Fatty acid oxidation in human skeletal muscle. J Clin Invest 2002;110:1607–
1609. 
29. Braun TP, Marks DL. Hypothalamic regulation of muscle metabolism. Curr Opin Clin 
Nutr Metab Care 2011;14(3):237-242. 
30. Lindberg D, Chen P, Li C. Conditional viral tracing reveals that steroidogenic factor 1-
positive neurons of the dorsomedial subdivision of the ventromedial hypothalamus 
project to autonomic centers of the hypothalamus and hindbrain. J Comp Neurol 
2013;521(14):3167-3190. 
31. da Silva AA, do Carmo JM, Kanyicska B, Dubinion J, Brandon E, Hall JE. Endogenous 
melanocortin system activity contributes to the elevated arterial pressure in spontaneously 
hypertensive rats. Hypertension 2008;51(4):884-890. 
32. Haynes WG, Morgan DA, Djalali A, Sivitz WI, Mark AL. Interactions between the 
melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 
1999;33(1 Pt 2):542-547. 
33. Lessard SJ, Rivas DA, Chen ZP, et al. Impaired skeletal muscle beta-adrenergic 
activation and lipolysis are associated with whole-body insulin resistance in rats bred for 
low intrinsic exercise capacity. Endocrinology 2009;150(11):4883-4891.  
34. Overmyer KA, Evans CR, Qi NR, et al. Maximal oxidative capacity during exercise is 
associated with skeletal muscle fuel selection and dynamic changes in mitochondrial 
protein acetylation. Cell metabolism 2015;21:468–478. 
35. Alekseev AE, Reyes S, Yamada S, et al. Sarcolemmal ATP-sensitive K(+) channels 
Page 24 of 56
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
25 
control energy expenditure determining body weight. Cell Metab 2010;11(1):58-69.  
36. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB. Leptin 
stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 
2002;415(6869):339-343.  
37. Nogueiras R, Wiedmer P, Perez-Tilve D, et al. The central melanocortin system directly 
controls peripheral lipid metabolism. J Clin Invest 2007;117(11):3475-3488.  
38. Sohn JW, Harris LE, Berglund ED, et al. Melanocortin 4 receptors reciprocally regulate 
sympathetic and parasympathetic preganglionic neurons. Cell 2013;152(3):612-619.  
Page 25 of 56
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t Table 1. Norepinephrine turnover (ng NE/g tissue/hr) in high-capacity runners (HCR) and low-
capacity runners (LCR) 4 hrs after intra-ventromedial hypothalamic microinjection of either the 
mixed melanocortin receptor agonist MTII or vehicle. Mean±SEM 
 
Tissue 
HCR LCR 
vehicle MTII* vehicle MTII* 
White 
adipose 
tissue 
Mesenteric†** 
18.88** 
±2.30 
38.73** 
±4.72 
8.39 
±0.71 
15.24 
±1.30 
Retroperitoneal 
8.04 
±0.70 
13.99 
±1.23 
6.32 
±0.87 
11.34 
±1.56 
Epididymal†** 
5.22** 
±0.60 
7.58** 
±0.87 
2.05 
±0.11 
5.56 
±0.31 
Gluteal†** 
4.92 
±0.30 
7.95** 
±0.49 
4.19 
±0.37 
4.52 
±0.40 
Inguinal†** 
2.29 
±0.19 
3.88** 
±0.32 
1.90 
±0.17 
2.43 
±0.22 
Brown adipose tissue†** 
27.45** 
±1.54 
62.50** 
±3.51 
18.36 
±1.06 
30.91 
±1.78 
Liver† 
0.85 
±0.10 
2.11** 
±0.26 
0.66 
±0.06 
1.17 
±0.10 
 
HCR, high-capacity runners; LCR, low-capacity runners (N=7/HCR, 8/LCR) 
*MTII>vehicle, within line (HCR/LCR) when interaction was significant; all tissues showed 
main effect of MTII; p<0.05 
**HCR≠LCR within treatment indicated; main effect of line (HCR/LCR) indicated on tissue; 
p<0.05 
†
Significant interaction between treatment (vehicle/MTII) and line (HCR/LCR); p<0.05 
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tTable 2. Changes in relative mRNA expression after intra-ventromedial hypothalamic treatment 
with the melanocortin receptor agonist MTII. In percent of vehicle-treated HCR, mean±SEM 
 
Tissue  
HCR LCR 
vehicle MTII vehicle MTII 
Brown 
Adipose 
Tissue 
B3-AR 100.0±7.6 101±12.8 80.3±5.2 89.6±10.7 
UCP1*,** 100.0±5.1 129±5.1 65.9±7.9 82.6±5.4 
PPARα*,** 100.0±7.1 132±5.8 73.8±6.5 90.7±7.9 
PPARδ** 100.0±8.0 133±5.5 71.8±6.1 87.7±5.8 
PPARγ*,** 100.0±2.0 123±4.7 79.6±4.3 92.7±5.9 
PGC-1α*,** 100.0±9.6 144±10.5 68.3±9.4 89.2±7.9 
White 
Adipose 
Tissue 
Β3-AR*,** 100.0±6.3 116.0±10.5 76.9±7.4 85.9±5.5 
UCP2** 100.0±8.9 110.6±8.3 67.9±7.5 73.9±8.7 
PPARα*,** 100.0±5.5 132.4±7.3 67.9±7.9 91.6±4.1 
PPARδ*,** 100.0±9.7 136.5±5.7 65.0±10.1 97.3±7.5 
PPARγ*,** 100.0±8.1 129.7±8.5 72.5±6.9 89.1±8.4 
PGC-1α** 100.0±5.2 112.9±7.6 70.9±9.6 75.6±8.8 
Liver 
Β2-AR*,** 100.0±7.8 117.6±6.9 75.5±5.7 95.4±9.9 
UCP2*,** 100.0±5.3 129.9±8.4 79.5±6.4 95.9±9.8 
PPARα*,** 100.0±8.2 149.7±10.8 78.3±7.0 109.6±6.8 
PPARδ*,**† 100.0±6.2 172.2±7.2 72.4±7.0 111.0±9.6 
PPARγ*,** 100.0±9.5 164.5±15.4 76.2±5.9 115.0±3.5 
PGC-1α*,** 100.0±4.7 159.8±9.8 72.0±6.0 113.0±8.9 
 
HCR, high-capacity runners; LCR, low-capacity runners; B2-AR, beta-2 adrenergic receptor; 
B3-AR, beta-3 adrenergic receptor; PPAR, peroxisome proliferator activated protein; PGC-1α, 
PPARγ coactivator-1α; UCP, uncoupling protein. *MTII>vehicle; ** HCR≠LCR 
†
Significant 
interaction between treatment (vehicle/MTII) and line (HCR/LCR); p<0.05. (N=8/group) 
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tTable 3. Changes in relative protein level after intra-ventromedial hypothalamic treatment with the melanocortin receptor agonist MTII. In percent of vehicle-treated HCR, or as a ratio to 
unphosphorylated protein, mean±SEM. 
Tissue  
HCR LCR 
vehicle MTII vehicle MTII 
Gastroc-
nemius 
Β2-AR** 100.0±5.7 111.6±5.9 80.0±5.2 85.7±5.2 
UCP2*,** 100.0±6.3 108.0±6.4 75.4±6.1 78.6±5.5 
UCP3*,** 100.0±5.6 111.4±5.8 74.0±6.2 77.0±5.4 
PPARα** 100.0±5.2 110.0±6.1 79.7±5.2 85.3±5.4 
PPARδ** 100.0±5.9 113.0±6.4 76.5±5.6 86.0±6.8 
PPARγ** 100.0±5.4 116.7±6.4 77.4±5.5 85.3±5.3 
PGC-1α*,** 100.0±5.6 121.6±4.8 71.7±5.4 79.3±5.2 
CPT1 100.0±6.5 111.7±6.0 89.6±6.0 96.9±5.4 
SERCA1*,** 100.0±4.9 116.5±5.8 74.9±5.2 84.0±6.7 
SERCA2** 100.0±6.0 115.9±5.2 69.5±5.2 74.4±5.6 
Kir6.1** 100.0±4.7 97.7±5.6 119.7±4.3 118.0±7.9 
Kir6.2** 100.0±5.9 97.3±4.8 129.7±5.4 129.5±5.7 
MED1** 100.0±5.0 99.9±5.4 131.7±5.6 128.9±5.9 
FAS 100.0±5.7 97.9±5.4 92.6±5.9 92.4±6.0 
CD36 (FAT)** 100.0±6.2 111.0±5.8 82.0±5.4 87.9±6.6 
ACC 100.0±5.4 99.8±5.5 107.9±5.7 104.4±5.5 
pACC*,** 100.0±5.2 121.4±4.9 78.2±5.4 89.5±5.8 
pACC/ACC*,** 100.2±4.5 122.3±5.5 73.0±7.6 87.3±9.8 
AMPK 100.0±5.4 100.5±5.0 99.9±5.7 99.4±5.5 
pAMPK*,** 100.0±5.2 122.0±4.5 97.2±5.5 91.6±5.4 
pAMPK/AMPK*,** 100.4±6.3 123.0±10.6 79.6±6.1 92.2±3.4 
Quadriceps 
Β2-AR** 100.0±6.7 105.9±6.9 83.7±5.2 87.5±6.7 
UCP2** 100.0±6.1 106.6±7.0 74.4±6.4 76.6±5.4 
UCP3** 100.0±5.7 108.4±5.9 73.0±6.8 75.5±5.8 
PPARα** 100.0± 108.0±8.2 85.0±7.4 89.0±5.9 
PPARδ** 100.0± 102.5±6.9 85.5±5.4 84.7±7.8 
PPARγ** 100.0± 112.5±6.5 83.7±5.4 89.1±5.8 
PGC-1α** 100.0±5.3 111.9±5.2 70.2±5.8 76.3±5.9 
CPT1 100.0±6.5 109.9±6.0 92.6±5.7 102.9±5.4 
SERCA1** 100.0±4.9 114.8±5.8 78.5±5.2 87.0±6.7 
SERCA2** 100.0±5.0 110.9±5.2 76.5±5.7 83.7±6.6 
Kir6.1 100.0±5.7 98.3±5.8 112.9±4.2 109.5±6.9 
Kir6.2** 100.0±4.9 96.7±5.9 126.8±4.4 123.2±5.9 
MED1** 100.0±4.7 98.7±5.8 129.8±5.9 127.0±5.0 
FAS 100.0±6.0 98.7±6.4 98.4±5.6 99.4±6.6 
CD36 (FAT) ** 100.0±7.2 103.0±6.1 95.8±6.1 86.4±7.6 
ACC 100.0±6.5 99.0±6.0 106.6±5.7 102.9±5.4 
pACC** 100.0±6.0 113.8±4.8 89.4±5.8 96.4±5.9 
pACC/ACC** 100.8±8.1 117.1±11.3 85.3±9.1 93.4±3.3 
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t AMPK 100.0±7.5 99.5±7.6 99.8±6.8 99.4±5.5 pAMPK*,** 100.0±5.0 117.0±4.6 98.6±5.5 89.7±5.3 pAMPK/AMPK** 100.6±7.3 118.2±7.7 79.3±6.7 90.6±5.9 
Brown 
Adipose 
Tissue 
Β3-AR** 100.0±6.3 107.4±8.0 76.3±5.5 88.9±7.8 
UCP1*,** 100.0±3.9 119.4±4.0 65.8±4.9 76.2±3.5 
PPARα 100.0±7.4 115.0±9.8 88.2±8.7 95.7±5.6 
PPARδ 100.0±5.9 107.9±6.7 93.8±4.3 98.8±7.5 
PPARγ** 100.0±4.6 106.5±6.8 78.2±6.3 87.9±7.7 
PGC-1α*,** 100.0±5.4 123.2±6.0 78.0±4.3 85.1±7.2 
CPT1 100.0±6.5 112.8±5.3 78.6±5.4 90.4±7.3 
FAS 100.0±6.3 98.9±5.0 100.9±4.8 99.8±5.8 
CD36 (FAT)** 100.0±9.1 102.6±7.3 90.5±6.5 95.4±6.2 
ACC 100.0±7.3 99.5±6.7 103.7±5.7 104.2±7.6 
pACC*,** 100.0±4.3 126.8±7.1 89.4±6.0 99.8±5.3 
pACC/ACC*,** 100.5±5.8 127.3±1.5 86.4±3.8 97.6±9.9 
AMPK 100.0±6.5 98.6±5.3 101.7±3.8 100.4±7.3 
pAMPK*,** 100.0±5.9 138.7±7.3 79.9±5.7 97.3±7.3 
pAMPK/AMPK*,** 100.8±8.4 141.8±11.2 76.9±3.9 97.5±4.0 
White 
Adipose 
Tissue 
Β3-AR** 100.0±5.5 109.0±6.0 80.6±4.6 86.0±6.6 
UCP2** 100.0±5.3 106.0±4.4 89.3±4.8 92.7±5.6 
PPARα 100.0±5.3 111.6±5.9 86.4±6.1 94.2±6.9 
PPARδ 100.0±3.5 106.6±4.2 92.8±4.9 99.5±3.7 
PPARγ 100.0±6.5 102.7±8.2 98.6±5.9 100.9±6.4 
PGC-1α** 100.0±5.9 111.4±6.5 91.8±4.4 99.3±7.2 
FAS 100.0±7.6 96.4±7.3 101.9±5.9 99.8±6.2 
CD36 (FAT) 100.0±5.8 99.6±6.5 104.3±6.8 104.1±5.3 
ACC 100.0±6.3 99.9±5.8 104.4±6.2 103.9±6.2 
pACC 100.0±5.8 112.0±4.4 93.8±5.7 105.4±5.7 
pACC/ACC 100.3±2.1 112.9±6.5 90.7±8.9 102.1±7.5 
AMPK 100.0±5.8 99.8±4.2 100.8±5.4 99.9±5.4 
pAMPK* 100.0±5.9 122.7±5.0 98.1±5.6 107.9±5.6 
pAMPK/AMPK 100.7±9.3 125.1±11.1 98.4±8.4 108.3±2.9 
Liver 
Β2-AR** 100.0±5.0 105.8±6.9 80.4±5.4 89.5±5.5 
UCP2** 100.0±5.1 109.8±5.9 79.9±4.6 86.5±5.2 
PPARα 100.0±6.9 113.6±5.7 89.3±5.4 99.1±4.9 
PPARδ** 100.0±6.3 117.6±6.4 83.7±5.2 91.7±5.6 
PPARγ** 100.0±5.4 115.4±5.9 76.8±5.7 85.2±6.3 
PGC-1α** 100.0±5.8 108.4±4.9 86.5±4.8 87.2±5.7 
CPT1 100.0±5.2 105.3±6.4 88.7±5.2 97.0±4.0 
FAS 100.0±5.5 98.5±6.1 100.8±5.2 101.7±5.8 
CD36 (FAT)** 100.0±4.0 95.7±5.4 111.5±4.9 109.8±4.8 
ACC 100.0±6.2 99.5±5.3 104.8±5.2 105.7±6.7 
pACC 100.0±5.4 125.4±6.8 89.3±5.5 94.2±6.7 
pACC/ACC** 101.2±10.5 126.7±2.1 86.6±9.1 90.0±7.5 
AMPK 100.0±5.9 100.0±6.0 100.3±6.1 100.5±5.4 
pAMPK*,** 100.0±5.2 122.7±5.4 89.7±5.2 95.8±5.0 
pAMPK/AMPK** 100.2±4.9 123.1±4.4 90.0±8.4 96.7±10.4 
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tHCR, high-capacity runners; LCR, low-capacity runners; B2-AR, beta-2 adrenergic receptor; B3-AR, beta-3 adrenergic receptor; PPAR, peroxisome proliferator activated protein; PGC-1α, 
PPARγ coactivator-1α; UCP, uncoupling protein; CPT1, carnitine-palmitoyl transferase 1; 
SERCA, sarcoplasmic-endoplasmic reticulum calcium ATPase; Kir, inwardly-rectifying 
potassium channel; MED1, Mediator of RNA polymerase II transcription subunit 1; FAS, fatty 
acid synthase; CD36/FAT, cluster of differentiation 36/fatty acid translocase; ACC, acetyl-CoA 
carboxylase; AMPK, AMP-activated protein kinase. *MTII>vehicle; **HCR≠LCR; p<0.05 
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Figure 1: High-capacity runners (HCR) were more responsive to the ability of intra-ventromedial 
hypothalamic (VMH) melanocortin receptor activation to enhance activity-related energy expenditure (EE). 
Low-capacity runners (LCR) and HCR were given intra-VMH microinjections of the mixed melanocortin 
receptor agonist melanotan II (MTII, gray bars) or vehicle (veh; black bars). Over 4 hours, intra-VMH MTII 
significantly increased free-moving EE (A), VO2 (B), and physical activity (D), while decreasing respiratory 
exchange ratio (RER; C). HCR showed a significantly greater MTII-induced increase in VO2 and physical 
activity. Intra-VMH MTII also induced changes in EE and RER in rats walked on a treadmill at 7 meters/min 
for 30 min. MTII increased activity-associated EE (E) and VO2 (F), and decreased RER (G) in HCR and LCR. 
HCR showed lower overall walking-induced RER, while intra-VMH MTII produced a larger RER decrease in 
LCR than HCR (G), whereas HCR were more responsive to MTII-induced enhancement of activity EE (H). 
*within group, MTII treatment significantly different from veh; **HCR significantly different from LCR within 
treatment; p<0.05. (N=10)  
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Figure 2: (A) Low and moderate intensity treadmill activity increased skeletal muscle (gastrocnemius) 
temperature in high-capacity runners (HCR; circles) and low-capacity runners (LCR; triangles) after intra-
ventromedial hypothalamic (VMH) microinjections of the mixed melanocortin receptor agonist melanotan II 
(MTII; open symbols) or vehicle (veh; dark symbols). (B) Walking-induced increase in muscle temperature 
from baseline were significantly higher in HCR, whereas intra-VMH MTII significantly increased activity-
associated muscle heat dissipation in LCR but not HCR. *LCR, MTII treatment significantly different from 
veh; ** HCR > LCR, main effect (A) and difference at baseline (B); p<0.05. (N=10/HCR, 6/LCR)  
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Figure 3: Norepinephrine turnover (NETO) showed differences in sympathetic drive in high- and low-capacity 
runners (HCR. LCR) after intra-ventromedial hypothalamic (VMH) microinjections of the mixed melanocortin 
receptor agonist melanotan II (MTII; gray bars) or vehicle (veh; black bars). Intra-VMH MTII significantly 
increased NETO in skeletal muscle including (A) medial gastrocnemius, (B) lateral gastrocnemius, (C) 
quadriceps, (D) soleus, and (E) extensor digitorum longus (EDL); HCR showed significantly higher NETO in 
each of these muscle groups, and also had significantly greater MTII-induced NETO in lateral gastrocnemius, 
quadriceps, soleus, and EDL. (F) Intra-VMH MTII also increased NETO in heart, but heart NETO was higher 
in LCR than HCR. *within group, MTII treatment significantly different from veh; **HCR significantly 
different from LCR within treatment; p<0.05. (N=7/HCR, 8/LCR)  
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Figure 4: Intra-ventromedial hypothalamic (VMH) microinjections of the melanotan II (MTII) altered mRNA 
expression of energetic mediators in skeletal muscle (A: medial gastrocnemius; B: quadriceps) in high-and 
low-capacity runners (HCR, LCR). Beta2: β2 adrenergic receptor; UCP2 and 3: uncoupling protein 2 and 3; 
PPARa, d, and g: peroxisome proliferator-activated receptor α, δ, and γ; SERCA 1 and 2: sarco/endoplasmic 
reticulum ATPase 1 and 2; Kir6.1 and 6.1: subunits of the ATP-gated K+ channel, Med1: mediator of RNA 
polymerase II transcription subunit 1. HCR-MTII ≠ LCR-MTII in all cases. *within group, MTII treatment 
significantly different from veh; p<0.05. (N=8/group)  
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Home-cage gastrocnemius and BAT temperatures after intra-VMH MTII in HCR and 
LCR. 
 
Hind limb muscle and BAT temperatures were measured at baseline and every 15 min for 240 
min after intra-VMH vehicle or MTII microinjection in HCR and LCR. Changes in temperature 
from individual baseline values were calculated to factor out individual differences in baseline 
temperature. Intra-VMH MTII induced some change in temperature in BAT in HCR and LCR 
rats (Figure S1), but was less effective in inducing changes in muscle temperature (Figure S2).  
For BAT, there was a small increase in temperature which peaked about one hour after injection. 
There was a main effect of time but not MTII on BAT temperature, and a significant interaction 
where the effect of MTII depended on the time after injection. Because of the significant 
interaction between line and time, HCR and LCR were analyzed separately; in both lines, there 
was a main effect of MTII and an interaction between MTII and time, where the MTII-induced 
BAT thermogenesis depended on time since treatment.  
There was a significant interaction in change in BAT temperature from baseline where MTII 
induced a significant deviation from baseline temperature but vehicle microinjection did not. 
There were also significant main effects of time and MTII, and an interaction between line and 
time since injection (see Figure S1). 
In both the left and right gastrocnemius muscles groups, there was a main effect of time where 
temperature changed over time. This follows the daily rhythm in baseline muscle temperature we 
have demonstrated previously (where temperature falls throughout the light phase), which in turn 
follows the daily rhythm in physical activity levels. There were no main effects of line 
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gastrocnemius showed a significant interaction where HCR and LCR showed different 
temperatures depending on the time after injection, but this did not interact with MTII. Similarly, 
for the mean temperature of both left and right gastrocnemius, there was a main effect of time 
where mean gastrocnemius temperature changed over time, but no other main effects or 
interactions. 
As shown in Figure S2, when change in gastrocnemius temperature was calculated according to 
each rat’s baseline temperature, there were no significant main effects of line or MTII, but the 
right gastrocnemius showed a main effect of time where the change in temperature from baseline 
changed over time (trend in the left gastrocnemius, p=0.057). There was a significant MTII-by-
time interaction where the right gastrocnemius showed a significant increase in temperature from 
baseline in the right leg in the latter half of the test, but this did not differ between HCR and 
LCR. Similarly, for the mean temperature of both left and right gastrocnemius, there was a main 
effect of time where change in temperature from baseline changed over time, but no other main 
effects or interactions. 
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Brown adipose tissue (BAT) change from 
baseline temperature in high- and low-capacity 
runners (HCR, LCR) after intra-ventromedial 
hypothalamic microinjection of vehicle (Veh) 
or the mixed melanocortin receptor agonist 
Melanotan II (MTII). Compared to vehicle 
microinjection, MTII induced a significantly 
greater increase in temperature above baseline temperature in both HCR (45 min-105 min, and at 
150 min after MTII) and LCR (15 min-105 min, and at 165 min after MTII; *p<0.05).  
 
 
 
 
 
Figure S2.  
Mean right and left gastrocnemius temperature 
over 4 hours in the home cage, increase above 
baseline temperature in high- and low-capacity 
runners (HCR, LCR) after intra-ventromedial 
hypothalamic microinjection of vehicle (Veh) 
or the mixed melanocortin receptor agonist 
Melanotan II (MTII). The increase in 
temperature above baseline levels changed over time, but there were not differences between 
HCR and LCR, and no significant effect of MTII compared to vehicle treatment. 
* 
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mRNA and protein expression 
Following assay IDs were obtained from IDT technologies for gene expression assays – Gapdh, 
Rn.PT. 39a.11180736.g; Beta3 adrenergic receptor, Rn.PT.58.35740415; UCP1, 
Rn.PT.56a.14277400; PPARα, Rn.PT.58.35766078; PPARδ, Rn.PT.58.6572075; PPARγ, 
Rn.PT.58.6036576; PGC1α, Rn.PT.58.37655048; UCP2, Rn.PT.58.12555837; UCP3, 
Rn.PT.58.17938212; SERCA1, Rn.PT.58.35312973; SERCA2, Rn.PT.58.8873034; Kir6.1, 
Rn.PT.58.38199111; Med1, Rn.PT.58.8279221. Probes were diluted as per IDT instructions 
before proceeding to quantification of gene expression. Data were calculated using ∆Ct method 
and all data are expressed using mean ± SEM relative to HCR vehicle group set at 100% 
 
To evaluate protein expression, primary antibodies against beta 3 adrenergic receptor, UCP1, 
PPARα, PPARδ, PPARγ, PGC1α, ACC, p-ACC, AMPK, p-AMPK, CD36, FAS, UCP2, beta2 
adrenergic receptor, UCP3, SERCA1, SERCA2 (ab101095, ab10983, ab8934, ab23673, 
ab41928, ab54481, ab45174, ab68191, ab80039, ab133448, ab64014,  ab22759, ab67241, 
ab182136, ab3477, ab2819, ab2861 respectively from Abcam); Kir6.2 and MED1 (sc-11226 and 
sc-5334 from Santa Cruz), and Kir6.1 (SAB2101220, Sigma-Aldrich) were obtained and 
incubated with the blot overnight at 4°C and with either anti-rabbit or anti-mouse secondary 
(ab6721, ab6789 respectively from Abcam) for 1 hr at room temperature. Blots were developed 
using an Amersham chemiluminescence kit and data expressed as mean ± SEM relative to HCR 
vehicle group set at 100%. 
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Figure S3. Representative Western blot images of (A) brown adipose tissue (BAT) and (B) 
gastrocnemius (gastroc) muscle of HCR and LCR treated with either the non-specific 
melanocortin receptor agonist Melanotan II (MTII) or vehicle (aCSF) in the ventromedial 
hypothalamus. 
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tTable S1. Body weight and composition in high- and low-capacity runners (HCR, LCR) treated 
with vehicle (veh) and melanotan II (MTII); Mean±SEM 
 
  
HCR LCR 
Experiment 
 
vehicle MTII 
percent 
change 
vehicle MTII 
percent 
change 
Home-cage 
gastrocnemius & 
BAT temperature 
BW 
413.31 
±18.75 
410.15 
±18.86 
veh>MTII 
0.77% 
500.11 
±21.15 
496.01 
±20.85 
veh>MTII 
0.83% 
4-hr energy 
expenditure 
BW 
407.92 
±19.21 
410.60 
±18.89  
494.13 
±19.79 
496.27 
±20.43  
fat mass 
66.99 
±7.49 
67.3 
±7.50  
106.76 
±11.70 
107.5 
±11.49  
lean mass 
252.26 
±10.57 
255.44 
±10.70 
MTII>veh 
1.26% 
288.51 
±11.05 
286.50 
±11.24  
Treadmill activity 
thermogenesis 
BW 
405.63 
±19.28 
408.33 
±19.41 
MTII>veh 
0.67% 
487.53 
±26.54 
490.19 
±27.92  
fat mass 
68.29 
±7.20 
68.76 
±7.22 
MTII>veh 
0.69% 
106.73 
±15.74 
107.43 
±16.16  
lean mass 
255.20 
±11.62 
256.8 
±11.69 
MTII>veh 
0.66% 
285.3 
±8.62 
286.78 
±9.33  
Treadmill activity 
energy expenditure 
BW 
401.00 
±18.59 
403.64 
±19.52  
505.55 
±21.12 
500.29 
±20.90 
veh>MTII 
1.05% 
fat mass 
59.48 
±6.84 
60.00 
±7.40  
114.65 
±13.18 
110.27 
±12.48  
lean mass 
251.20 
±10.24 
260.61 
±11.51  
293.62 
±11.63 
283.88 
±10.65 
veh>MTII 
3.43% 
 
Percent change reported on values that showed significant change between treatments, within 
line (p<0.05). Body weights taken immediately before microinjection; lean and fat mass 
measured 2 days prior to microinjection. BAT, brown adipose tissue; BW, body weight. 
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tTable S2. Statistical results from analyses examining the effect of intra-ventromedial hypothalamic (VMH) Melanotan II (MTII) and vehicle on gas-exchange variables and physical 
activity in high- and low-capacity runners (HCR, LCR).   
Home-cage energy expenditure 
Main effects 
Interaction 
MTII/vehicle HCR/LCR 
 
VO2 
(ml/kg/hr) 
F 314.85 26.925 20.585 
df 1,19 1,19 1,19 
p <0.001 <0.001 <0.001 
VCO2 
(ml/kg/hr) 
F 244.741 28.812 22.3 
df 1,19 1,19 1,19 
p <0.001 <0.001 <0.001 
RER 
F 43.193 0.031 0.053 
df 1,19 1,19 1,19 
p <0.001 0.863 0.820 
EE (kcal/hr) 
F 323.878 0.668 9.415 
df 1,19 1,19 1,19 
p <0.001 0.424 0.006 
Horizontal 
activity 
counts 
F 92.459 9.563 12.292 
df 1,19 1,19 1,19 
p <0.001 0.006 0.049524 
Ambulatory 
activity 
counts 
F 63.003 4.263 0.536 
df 1,19 1,19 1,19 
p <0.001 0.048 0.473 
Vertical 
activity 
counts 
F 1.145 11.927 0.542 
df 1,19 1,19 1,19 
p 0.707 0.003 0.471 
Analysis of covariance 
EE with body 
weight as 
covariate 
F 0.224 9.694 15.062 
df 1,17 1,17 1,17 
p 0.642 0.006 0.001 
EE with lean 
mass as 
covariate 
F 0.657 12.406 8.474 
df 1,17 1,17 1,17 
p 0.429 0.003 0.010 
Each covariate was significant, and there were no interactions between treatment (effect of MTII) 
and covariates 
EE, energy expenditure; RER, respiratory exchange ratio (VCO2/VO2). 
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tTable S3. Statistical results from analyses examining the effect of intra-ventromedial hypothalamic (VMH) Melanotan II (MTII) and vehicle on gas-exchange variables in high- and 
low-capacity runners (HCR, LCR) during treadmill walking activity (walking 7 meters/min for 
30 min).   
Treadmill energy expenditure 
Main effects 
Interaction 
MTII/vehicle HCR/LCR 
 
VO2 (ml/kg/hr) 
F 27.266 1.604 3.473 
df 1,14 1,14 1,14 
p <0.001 0.226 0.084 
VCO2 
(ml/kg/hr) 
F 0.976 0.081 26.192 
df 1,14 1,14 1,14 
p 0.34 0.781 <0.001 
RER 
F 57.619 23.059 5.461 
df 1,14 1,14 1,14 
p <0.001 <0.001 0.035 
EE (kcal/hr) 
F 38.207 7.136 11.114 
df 1,14 1,14 1,14 
p <0.001 0.018 0.005 
Analysis of covariance 
EE with body 
weight as 
covariate 
F 0.079 0.198 8.555 
df 1,13 1,13 1,13 
p 0.783 0.664 0.012 
EE with lean 
mass as 
covariate 
F 0.15 2.342 8.946 
df 1,13 1,13 1,13 
p 0.705 0.15 0.100 
Each covariate was significant, and there were no interactions between treatment (effect of MTII) 
and covariates 
EE, energy expenditure; RER, respiratory exchange ratio (VCO2/VO2). 
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tTable S4. Statistical results from analyses examining the effect of intra-ventromedial hypothalamic (VMH) Melanotan II (MTII) and vehicle on gastrocnemius muscle temperature 
over the course of 4 hrs after treatment in high- and low-capacity runners (HCR, LCR).  
Home cage muscle 
temperature  
Main effects Interactions 
MTII/vehicle Time HCR/LCR 
Treatment 
x line 
Time 
x line 
Treatment 
x time 
Treatment x 
time x line 
Right leg temperature 
F 0.081 4.330 1.264 0.183 1.682 0.541 0.411 
df 1,19 16,4 1,19 1,19 16,4 16,4 16,4 
p 0.779 <0.001 0.275 0.673 0.049 0.924 0.979 
Left leg temperature 
F 1.170 1.826 0.693 0.001 1.289 0.924 0.533 
df 1,19 16,4 1,19 1,19 16,4 16,4 16,4 
p 0.393 0.027 0.415 0.975 0.202 0.542 0.929 
Average L and R leg 
temperature 
F 0.129 2.622 1.001 0.066 1.610 0.760 0.296 
df 1,19 16,4 1,19 1,19 16,4 16,4 16,4 
p 0.724 0.001 0.330 0.801 0.065 0.730 0.997 
Right leg temperature 
change from baseline 
F 2.973 2.939 0.842 0.295 1.354 2.454 0.436 
df 1,19 16,4 1,19 1,19 16,4 16,4 16,4 
p 0.101 <0.001 0.370 0.593 0.164 0.002 0.972 
Left leg temperature 
change from baseline 
F 0.091 1.644 1.138 0.338 1.655 0.633 0.359 
df 1,19 16,4 1,19 1,19 16,4 16,4 16,4 
p 0.766 0.057 0.229 0.568 0.055 0.856 0.990 
Average R and L leg 
temperature change 
from baseline 
F 0.550 2.622 1.183 0.003 1.610 0.760 0.296 
df 1,19 16,4 1,19 1,19 16,4 16,4 16,4 
p 0.467 0.001 0.290 0.957 0.065 0.730 0.997 
BAT temperature 
F 0.260 29.481 0.042 0.372 2.471 5.363 0.503 
df 1,19 16,4 1,19 1,19 16,4 16,4 16,4 
p 0.616 <0.001 0.841 0.549 0.002 p<0.001 0.945 
BAT temperature 
change from baseline 
F 8.816 29.481 0.072 0.005 2.471 5.363 0.503 
df 1,19 16,4 1,19 1,19 16,4 16,4 16,4 
p 0.008 <0.001 0.792 0.945 0.002 <0.01 0.945 
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tTable S5. Statistical results from analyses examining the effect of intra-ventromedial hypothalamic (VMH) Melanotan II (MTII) and vehicle on gastrocnemius muscle temperature 
during treadmill walking in high- and low-capacity runners (HCR, LCR).   
Treadmill-activity muscle 
temperature 
Main effects Interactions 
MTII/vehicle Time HCR/LCR 
Treatment 
x line 
Time x 
line 
Treatment 
x time 
Treatment 
x time x 
line 
Right leg 
temperature 
F 1.470 127.156 0.016 0.007 20.176 3.773 3.524 
df 1,14 5,10 1,14 1,14 5,10 5,10 5,10 
p 0.245 <0.001 0.900 0.933 <0.001 0.004 0.007 
Left leg temperature 
F 0.224 199.702 0.091 0.001 19.409 3.161 2.534 
df 1,14 5,10 1,14 1,14 5,10 5,10 5,10 
p 0.643 <0.001 0.767 0.971 <0.001 0.120 0.036 
Average L and R leg 
temperature 
F 0.860 190.009 0.006 0.005 24.529 4.772 4.219 
df 1,14 5,10 1,14 1,14 5,10 5,10 5,10 
p 0.370 <0.001 0.937 0.947 <0.001 0.001 0.002 
Right leg 
temperature change 
from baseline 
F 0.878 127.165 16.039 0.878 20.176 3.773 3.524 
df 1,14 5,10 1,14 1,14 5,10 5,10 5,10 
p 0.365 <0.001 0.001 0.365 <0.001 0.004 0.007 
Left leg temperature 
change from baseline 
F 2.754 199.702 17.345 0.172 19.409 3.161 2.534 
df 1,14 5,10 1,14 1,14 5,10 5,10 5,10 
p 0.119 <0.001 0.001 0.685 <0.001 0.120 0.036 
Average R and L leg 
temperature change 
from baseline 
F 2.577 199.009 18.920 0.706 24.529 4.772 4.219 
df 1,14 5,10 1,14 1,14 5,10 5,10 5,10 
p 0.131 <0.001 0.001 0.415 <0.001 0.001 0.002 
BAT temperature 
(before and after 
activity) 
F 1.170 11.051 1.061 1.453 10.000 2.133 0.050 
df 1,14 1,14 1,14 1,14 1,14 1,14 1,14 
p 0.231 <0.001 0.320 0.248 0.007 0.166 0.825 
BAT temperature 
change from baseline 
F 2.133 
N/A 
10.000 0.050 
N/A N/A N/A df 1,14 1,14 1,14 
p 0.166 0.007 0.825 
Analysis included temperatures though 20 min of treadmill walking to encompass data for all rats, 
before any rats became noncompliant with treadmill-waling protocol. BAT temperatures were measured 
once before and once after treadmill walking (significant decrease over time, larger decrease in HCR). 
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BAT 
F 572.245 52.627 127.835 
df 1,13 1,13 1,13 
p <0.001 <0.001 <0.001 
MWAT 
F 115.306 21.661 27.274 
df 1,13 1,13 1,13 
p <0.001 <0.001 <0.001 
RWAT 
F 160.033 1.961 1.116 
df 1,13 1,13 1,13 
p <0.001 0.183 0.309 
EWAT 
F 309.205 11.503 11.883 
df 1,13 1,13 1,13 
p <0.001 0.004 0.004 
GWAT 
F 314.589 13.91 202.977 
df 1,13 1,13 1,13 
p <0.001 0.002 <0.001 
IWAT 
F 258.613 8.474 65.392 
df 1,13 1,13 1,13 
p <0.001 0.012 <0.001 
Liver 
F 107.912 7.332 19.324 
df 1,13 1,13 1,13 
p <0.001 0.018 0.001 
Heart 
F 166.185 3.935 4.952 
df 1,13 1,13 1,13 
p <0.001 0.069 0.044 
Soleus 
F 276.059 70.096 46.498 
df 1,13 1,13 1,13 
p <0.001 <0.001 <0.001 
EDL 
F 392.559 9.193 6.119 
df 1,13 1,13 1,13 
p <0.001 0.009 0.027 
Quadriceps 
F 298.337 36.944 9.053 
df 1,13 1,13 1,13 
p <0.001 <0.001 0.009 
Lateral 
gastrocnemius 
F 290.798 17.969 10.142 
df 1,13 1,13 1,13 
p <0.001 0.001 0.007 
Medial 
gastrocnemius 
F 193.457 5.539 2.903 
df 1,13 1,13 1,13 
p <0.001 0.034 0.110 
Table S6. Statistical results from 
analyses examining the effect of 
intra-ventromedial hypothalamic 
(VMH) Melanotan II (MTII) and 
vehicle on norepinephrine turnover 
(NETO) in high- and low-capacity 
runners (HCR, LCR. 
 
BAT, brown adipose tissue; 
MWAT, mesenteric white adipose 
tissue; RWAT, retroperitoneal 
white adipose tissue; EWAT, 
epididymal white adipose tissue; 
GWAT, gluteal white adipose 
tissue; IWAT, inguinal white 
adipose tissue; EDL, extensor 
digitorum longus. 
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tTable S7. Statistical results from analyses examining the effect of intra-ventromedial hypothalamic (VMH) Melanotan II (MTII) and vehicle on brown adipose tissue (BAT) mRNA 
expression using qPCR in high- and low-capacity runners (HCR, LCR).   
 
Brown adipose 
tissue (BAT) 
Main effects 
Interaction 
t-test for MTII≠vehicle 
MTII/vehicle HCR/LCR HCR LCR 
β3-AR 
F 0.376 3.527 0.272 
  
df 1,28 1,28 1,28 
  
p 0.544 0.071 0.606 0.480 0.102 
UCP1 
F 19.477 60.218 1.437 
  
df 1,28 1,28 1,28 
  
p <0.001 <0.001 0.241 0.001 0.020 
PPARα 
F 19.502 37.072 1.892 
  
df 1,28 1,28 1,28 
  
p <0.001 <0.001 0.18 0.002 0.008 
PPARδ 
F 31.913 37.072 0.112 
  
df 1,28 1,28 1,28 
  
p <0.001 <0.001 0.74 0.000 0.024 
PPARγ 
F 23.261 46.191 1.736 
  
df 1,28 1,28 1,28 
  
p <0.001 <0.001 0.198 0.000 0.033 
PGC1α 
F 21.241 37.49 2.907 
  
df 1,28 1,28 1,28 
  
p <0.001 <0.001 0.099 0.001 0.007 
β3-AR, Beta-3 adrenergic receptor; UCP1, uncoupling protein 1; PPAR, peroxisome proliferator 
activated receptor; PGC1α, PPARγ coactivator-1α. 
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tTable S8. Statistical results from analyses examining the effect of intra-ventromedial hypothalamic (VMH) Melanotan II (MTII) and vehicle on white adipose tissue (WAT) mRNA 
expression using qPCR in high- and low-capacity runners (HCR, LCR).   
White adipose 
tissue (WAT) 
Main effects 
Interaction 
t-test for 
MTII≠vehicle 
MTII/vehicle HCR/LCR HCR LCR 
β3-AR 
F 4.877 22.009 0.375 
 
df 1,28 1,28 1,28 
 
p 0.36 <0.001 0.545 0.050 0.101 
UCP2 
F 2.184 37.707 0.168 
 
df 1,28 1,28 1,28 
 
p 0.151 <0.001 0.685 0.129 0.194 
PPARα 
F 22.384 37.856 0.536 
 df 1,28 1,28 1,28 
 p <0.001 <0.001 0.47 0.002 0.003 
PPARδ 
F 31.913 37.072 0.112 
 df 1,28 1,28 1,28 
 p <0.001 <0.001 0.74 0.001 0.000 
PPARγ 
F 14.813 31.963 1.163 
 df 1,28 1,28 1,28 
 p 0.001 <0.001 0.29 0.005 0.012 
PGC1α 
F 2.235 31.472 0.473 
 df 1,28 1,28 1,28 
 p 0.146 <0.001 0.497 0.066 0.295 
β3-AR, Beta-3 adrenergic receptor; UCP2, uncoupling protein 2; PPAR, peroxisome proliferator 
activated receptor; PGC1α, PPARγ coactivator-1α. 
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tTable S9. Statistical results from analyses examining the effect of intra-ventromedial hypothalamic (VMH) Melanotan II (MTII) and vehicle on liver mRNA expression using qPCR 
in high- and low-capacity runners (HCR, LCR).   
Liver 
Main effects 
Interaction 
t-test for 
MTII≠vehicle 
MTII/vehicle HCR/LCR HCR LCR 
β2-AR 
F 8.913 13.8 0.056 
  
df 1,28 1,28 1,28 
  
p 0.006 0.001 0.814 0.042 0.016 
UCP2 
F 14.544 20.254 1.239 
  
df 1,28 1,28 1,28 
  
p 0.001 <0.001 0.275 0.002 0.033 
PPARα 
F 31.701 18.427 1.608 
  
df 1,28 1,28 1,28 
  
p <0.001 <0.001 0.215 0.001 0.000 
PPARδ 
F 74.835 48.171 6.878 
  
df 1,28 1,28 1,28 
  
p <0.001 <0.001 0.014 0.000 0.000 
PPARγ 
F 31.376 15.815 1.938 
  
df 1,28 1,28 1,28 
  
p <0.001 <0.001 0.175 0.001 0.001 
PGC1α 
F 52.246 28.808 1.814 
  
df 1,28 1,28 1,28 
  
p <0.001 <0.001 0.189 0.000 0.000 
Β2-AR, Beta-2 adrenergic receptor; UCP2, uncoupling protein 2; PPAR, peroxisome proliferator 
activated receptor; PGC1α, PPARγ coactivator-1α. 
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tTable S10. Statistical results from analyses examining the effect of intra-ventromedial hypothalamic (VMH) Melanotan II (MTII) and vehicle on gastrocnemius mRNA expression 
using qPCR in high- and low-capacity runners (HCR, LCR).   
Gastrocnemius 
Main effects 
Interaction 
t-test for 
MTII≠vehicle 
MTII/vehicle HCR/LCR HCR LCR 
β2-AR 
F 9.498 22.179 2.201 
  
df 1,28 1,28 1,28 
  
p 0.005 <0.001 0.149 0.009 0.069 
UCP2 
F 13.382 19.927 0.388 
  
df 1,28 1,28 1,28 
  
p 0.001 <0.001 0.536 0.014 0.003 
UCP3 
F 23.574 15.735 0.293 
  
df 1,28 1,28 1,28 
  
p <0.001 <0.001 0.592 0.002 0.002 
PPARα 
F 14.728 17.598 0.31 
  
df 1,28 1,28 1,28 
  
p 0.001 <0.001 0.582 0.003 0.020 
PPARδ 
F 13.702 23.685 1.572 
  
df 1,28 1,28 1,28 
  
p 0.001 <0.001 0.22 0.004 0.030 
PPARγ 
F 22.747 15.151 1.714 
  
df 1,28 1,28 1,28 
  
p <0.001 0.001 0.201 0.001 0.003 
PGC1α 
F 9.778 13.544 0.474 
  
df 1,28 1,28 1,28 
  
p 0.004 0.001 0.497 0.016 0.030 
SERCA1 
F 11.077 25.884 2.067 
  
df 1,28 1,28 1,28 
  
p <0.001 <0.001 0.162 0.003 0.095 
SERCA2 
F 19.816 15.613 1.93 
  
df 1,28 1,28 1,28 
  
p <0.001 <0.001 0.176 0.003 0.001 
Kir6.1 
F 3.269 38.247 0.484 
  
df 1,28 1,28 1,28 
  
p 0.081 <0.001 0.492 0.059 0.206 
Kir6.2 
F 9.39 42.931 1.001 
  
df 1,28 1,28 1,28 
  
p 0.005 <0.001 0.326 0.003 0.102 
MED1 
F 2.071 18.853 0.268 
  
df 1,28 1,28 1,28 
  
p 0.161 <0.001 0.609 0.118 0.233 
Muscle 
abbreviations 
(Tables S10-
S11): 
 
Β2-AR, Beta-2 
adrenergic 
receptor; UCP2 
and 3, 
uncoupling 
protein 2 and 3; 
PPAR, 
peroxisome 
proliferator 
activated 
receptor; 
PGC1α, PPARγ 
coactivator-1α; 
SERCA, 
sarco/endoplas
mic reticulum 
Ca
2+
-ATPase; 
Kir6.1 and 6.2, 
components of 
ATP-gated K
+
-
channel; MED1, 
Mediator of 
RNA 
polymerase II 
transcription 
subunit 1. 
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tTable S11. Statistical results from analyses examining the effect of intra-ventromedial hypothalamic (VMH) Melanotan II (MTII) and vehicle on quadriceps mRNA expression using 
qPCR in high- and low-capacity runners (HCR, LCR).   
Quadriceps 
Main effects 
Interaction 
t-test for 
MTII≠vehicle 
MTII/vehicle HCR/LCR HCR LCR 
β2-AR 
F 4.352 20.736 0.269 
  
df 1,28 1,28 1,28 
  
p 0.046 <0.001 0.608 0.056 0.121 
UCP2 
F 15.45 18.064 1.042 
  
df 1,28 1,28 1,28 
  
p 0.001 <0.001 0.316 0.007 0.004 
UCP3 
F 18.581 27.072 1.723 
  
df 1,28 1,28 1,28 
  
p <0.001 <0.001 0.2 0.004 0.002 
PPARα 
F 7.746 32.282 0.855 
  
df 1,28 1,28 1,28 
  
p 0.01 <0.001 0.363 0.006 0.121 
PPARδ 
F 7.163 35.755 3.233 
  
df 1,28 1,28 1,28 
  
p 0.012 <0.001 0.083 0.006 0.253 
PPARγ 
F 3.829 31.905 1.311 
  
df 1,28 1,28 1,28 
  
p 0.06 <0.001 0.262 0.034 0.261 
PGC1α 
F 3.86 10.493 0.926 
  
df 1,28 1,28 1,28 
  
p 0.059 0.003 0.344 0.033 0.237 
SERCA1 
F 5.653 24.607 2.303 
  
df 1,28 1,28 1,28 
  
p 0.024 <0.001 0.14 0.010 0.266 
SERCA2 
F 4.886 57.654 1.1 
  
df 1,28 1,28 1,28 
  
p 0.035 <0.001 0.303 0.005 0.250 
Kir6.1 
F 3.206 31.955 0.017 
  
df 1,28 1,28 1,28 
  
p 0.084 <0.001 0.897 0.069 0.156 
Kir6.2 
F 1.401 16.331 0.046 
  
df 1,28 1,28 1,28 
  
p 0.246 <0.001 0.832 0.273 0.139 
MED1 
F 1.304 16.024 0.084 
  
df 1,28 1,28 1,28 
  
p 0.263 <0.001 0.774 0.261 0.182 
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tTable S12. Statistical results from analyses examining the effect of intra-ventromedial hypothalamic (VMH) Melanotan II (MTII) and vehicle on brown adipose tissue (BAT) protein 
expression using Western blot in high- and low-capacity runners (HCR, LCR).   
Brown adipose 
tissue (BAT) 
Main effects 
Interaction 
t-test for MTII≠vehicle 
MTII/vehicle HCR/LCR HCR LCR 
β3-AR 
F 2.644 11.725 0.192 
  
df 1,10 1,10 1,10 
  
p 0.135 0.007 0.671 0.258 0.054 
UCP1 
F 9.374 62.4 0.914 
  
df 1,10 1,10 1,10 
  
p 0.012 <0.001 0.362 0.009 0.125 
PPARα 
F 2.02 3.82 0.202 
  
df 1,10 1,10 1,10 
  
p 0.186 0.079 0.663 0.140 0.240 
PPARδ 
F 1.029 1.575 0.05 
  
df 1,10 1,10 1,10 
  
p 0.334 0.238 0.827 0.203 0.306 
PPARγ 
F 1.405 9.053 0.037 
  
df 1,10 1,10 1,10 
  
p 0.263 0.013 0.851 0.244 0.200 
PGC1α 
F 5.018 18.86 1.036 
  
df 1,10 1,10 1,10 
  
p 0.049 0.001 0.333 0.023 0.236 
ACC 
F 0.000 0.416 0.005 
  
df 1,10 1,10 1,10 
  
p 0.983 0.533 0.945 0.485 0.477 
pACC 
F 10.578 10.765 2.114 
  
df 1,10 1,10 1,10 
  
p 0.009 0.008 0.176 0.013 0.115 
AMPK 
F 0.039 0.053 0.000 
  
df 1,10 1,10 1,10 
  
p 0.847 0.822 0.996 0.438 0.453 
pAMPK 
F 14.061 16.655 1.558 
  
df 1,10 1,10 1,10 
  
p 0.004 0.002 0.24 0.008 0.069 
CD36 (FAT) 
F 0.24 1.324 0.016 
  
df 1,10 1,10 1,10 
  
p 0.635 0.277 0.903 0.412 0.323 
FAS 
F 0.037 0.02 0.000 
  
df 1,10 1,10 1,10 
  
p 0.852 0.89 0.992 0.447 0.450 
 
Table S12 
abbreviations: 
 
Β3-AR, Beta-3 
adrenergic 
receptor; UCP1, 
uncoupling 
protein 1; PPAR, 
peroxisome 
proliferator 
activated receptor; 
PGC1α, PPARγ 
coactivator-1α; 
(p)ACC, 
(phosphor-)acetyl-
CoA carboxylase; 
(p)AMPK, 
(phospho-)AMP-
activated protein 
kinase; CD36, 
fatty acid 
translocase; FAS, 
fatty acid 
synthase. 
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tTable S13. Statistical results from analyses examining the effect of intra-ventromedial hypothalamic (VMH) Melanotan II (MTII) and vehicle on white adipose tissue (WAT) protein 
expression using Western blot in high- and low-capacity runners (HCR, LCR).   
White adipose 
tissue (WAT) 
Main effects 
Interaction 
t-test for MTII≠vehicle 
MTII/vehicle HCR/LCR HCR LCR 
β3-AR 
F 1.87 15.865 0.089 
 
df 1,10 1,10 1,10 
 
p 0.201 0.003 0.772 0.135 0.251 
UCP2 
F 0.852 5.761 0.052 
  
df 1,10 1,10 1,10 
  
p 0.378 0.037 0.824 0.239 0.311 
PPARα 
F 1.446 1.677 0.000 
  
df 1,10 1,10 1,10 
  
p 0.257 0.224 0.996 0.151 0.256 
PPARδ 
F 0.127 0.056 0.001 
  
df 1,10 1,10 1,10 
  
p 0.729 0.817 0.971 0.408 0.400 
PPARγ 
F 2.453 2.831 0.11 
  
df 1,10 1,10 1,10 
  
p 0.148 0.123 0.747 0.098 0.230 
PGC1α 
F 2.448 6.458 0.108 
  
df 1,10 1,10 1,10 
  
p 0.149 0.029 0.749 0.105 0.225 
ACC 
F 0.003 0.479 0.000 
  
df 1,10 1,10 1,10 
  
p 0.959 0.505 1.000 0.486 0.486 
pACC 
F 4.04 1.222 0.000 
  
df 1,10 1,10 1,10 
  
p 0.072 0.297 0.988 0.110 0.105 
AMPK 
F 0.012 0.007 0.003 
  
df 1,10 1,10 1,10 
  
p 0.916 0.936 0.956 0.487 0.454 
pAMPK 
F 7.565 1.962 1.301 
  
df 1,10 1,10 1,10 
  
p 0.02 0.192 0.281 0.023 0.144 
CD36 (FAT) 
F 0.003 0.543 0.000 
  
df 1,10 1,10 1,10 
  
p 0.954 0.478 0.997 0.484 0.484 
FAS 
F 0.19 0.168 0.013 
  
df 1,10 1,10 1,10 
  
p 0.672 0.69 0.912 0.352 0.417 
 
Table S13 
abbreviations: 
 
Β3-AR, Beta-3 
adrenergic 
receptor; UCP2, 
uncoupling 
protein 2; PPAR, 
peroxisome 
proliferator 
activated receptor; 
PGC1α, PPARγ 
coactivator-1α; 
(p)ACC, 
(phosphor-)acetyl-
CoA carboxylase; 
(p)AMPK, 
(phospho-)AMP-
activated protein 
kinase; CD36, 
fatty acid 
translocase; FAS, 
fatty acid 
synthase. 
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tTable S14. Statistical results from analyses examining the effect of intra-ventromedial hypothalamic (VMH) Melanotan II (MTII) and vehicle on liver protein expression using Western 
blot in high- and low-capacity runners (HCR, LCR).  
Liver 
Main effects 
Interaction 
t-test for MTII≠vehicle 
MTII/vehicle HCR/LCR HCR LCR 
β2-AR 
F 1.715 9.737 0.131 
  
df 1,10 1,10 1,10 
  
p 0.22 0.011 0.725 0.283 0.123 
UCP2 
F 2.294 16.113 0.067 
  
df 1,10 1,10 1,10 
  
p 0.161 0.002 0.802 0.152 0.183 
PPARα 
F 3.693 4.178 0.096 
  
df 1,10 1,10 1,10 
  
p 0.084 0.068 0.763 0.110 0.121 
PPARδ 
F 4.3 11.853 0.629 
  
df 1,10 1,10 1,10 
  
p 0.065 0.006 0.446 0.054 0.194 
PPARγ 
F 3.628 17.526 0.265 
  
df 1,10 1,10 1,10 
  
p 0.086 0.002 0.618 0.054 0.209 
PGC1α 
F 0.693 10.01 0.521 
  
df 1,10 1,10 1,10 
  
p 0.425 0.01 0.487 0.181 0.467 
AMPK 
F 0.000 0.013 0.001 
  
df 1,10 1,10 1,10 
  
p 0.986 0.912 0.978 0.487 0.497 
pAMPK 
F 6.219 10.559 2.052 
  
df 1,10 1,10 1,10 
  
p 0.032 0.009 0.182 0.019 0.246 
CD36 (FAT) 
F 0.427 7.195 0.085 
  
df 1,10 1,10 1,10 
  
p 0.528 0.023 0.776 0.275 0.400 
FAS 
F 0.003 0.085 0.031 
  
df 1,10 1,10 1,10 
  
p 0.955 0.776 0.865 0.438 0.469 
 
 
 
 
 
 
 
Table S14 
abbreviations: 
 
Β3-AR, Beta-3 
adrenergic 
receptor; UCP1, 
uncoupling 
protein 1; PPAR, 
peroxisome 
proliferator 
activated receptor; 
PGC1α, PPARγ 
coactivator-1α; 
(p)AMPK, 
(phospho-)AMP-
activated protein 
kinase; CD36, 
fatty acid 
translocase; FAS, 
fatty acid 
synthase. 
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tTable S15. Statistical results from analyses examining the effect of intra-ventromedial hypothalamic (VMH) Melanotan II (MTII) and vehicle on gastrocnemius protein expression 
using Western blot in high- and low-capacity runners (HCR, LCR).  
 
Gastrocnemius 
Main effects 
Interaction 
t-test for MTII≠vehicle 
MTII/vehicle HCR/LCR HCR LCR 
β2-AR 
F 3.07 21.328 0.347 
  
df 1,10 1,10 1,10 
  
p 0.11 0.001 0.569 0.073 0.232 
UCP2 
F 1.019 23.156 0.131 
  
df 1,10 1,10 1,10 
  
p 0.337 0.001 0.725 0.183 0.337 
UCP3 
F 1.5585 27.783 0.572 
  
df 1,10 1,10 1,10 
  
p 0.237 <0.001 0.467 0.112 0.365 
PPARα 
F 2.658 18.262 0.006 
  
df 1,10 1,10 1,10 
  
p 0.134 0.002 0.941 0.157 0.142 
PPARδ 
F 3.653 18.654 0.089 
  
df 1,10 1,10 1,10 
  
p 0.085 0.002 0.771 0.106 0.130 
PPARγ 
F 4.359 20.371 0.517 
  
df 1,10 1,10 1,10 
  
p 0.063 0.001 0.489 0.059 0.177 
PGC1α 
F 5.534 31.995 1.272 
  
df 1,10 1,10 1,10 
  
p 0.04 <0.001 0.286 0.023 0.226 
SERCA1 
F 5.843 31.356 0.581 
  
df 1,10 1,10 1,10 
  
p 0.036 <0.001 0.463 0.026 0.169 
SERCA2 
F 3.609 42.549 0.991 
  
df 1,10 1,10 1,10 
  
p 0.087 <0.001 0.343 0.051 0.271 
Kir6.1 
F 0.161 12.388 0.000 
  
df 1,10 1,10 1,10 
  
p 0.697 0.006 0.998 0.384 0.402 
Kir6.2 
F 0.057 27.232 0.037 
  
df 1,10 1,10 1,10 
  
p 0.817 <0.001 0.851 0.377 0.489 
MED1 
F 0.085 33 0.057 
  
df 1,10 1,10 1,10 
  
p 0.777 <0.001 0.816 0.487 0.357 
Table S15-S16 
abbreviations: 
 
Β2-AR, Beta-2 
adrenergic 
receptor; UCP2 
and 3, uncoupling 
protein 2 and 3; 
PPAR, 
peroxisome 
proliferator 
activated receptor; 
PGC1α, PPARγ 
coactivator-1α; 
SERCA, 
sarco/endoplasmic 
reticulum Ca
2+
-
ATPase; Kir6.1 
and 6.2, 
components of 
ATP-gated K
+
-
channel; MED1, 
Mediator of RNA 
polymerase II 
transcription 
subunit 1; 
(p)AMPK, 
(phospho-)AMP-
activated protein 
kinase; CD36, 
fatty acid 
translocase; FAS, 
fatty acid 
synthase. 
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ACC 
F 0.118 1.134 0.102 
  
df 1,10 1,10 1,10 
  
p 0.738 0.312 0.756 0.494 0.321 
pACC 
F 10.516 28.566 0.986 
  
df 1,10 1,10 1,10 
  
p 0.009 <0.001 0.344 0.015 0.086 
AMPK 
F 0.002 0.012 0.001 
  
df 1,10 1,10 1,10 
  
p 0.965 0.917 0.973 0.479 0.497 
pAMPK 
F 11.619 25.222 0.757 
  
df 1,10 1,10 1,10 
  
p 0.007 0.001 0.405 0.012 0.074 
CD36 (FAT) 
F 2.41 14.068 0.156 
  
df 1,10 1,10 1,10 
  
p 0.152 0.004 0.701 0.114 0.224 
FAS 
F 0.04 1.211 0.024 
  
df 1,10 1,10 1,10 
  
p 0.845 0.297 0.879 0.408 0.488 
 
Table S16. Statistical results from analyses examining the effect of intra-ventromedial 
hypothalamic (VMH) Melanotan II (MTII) and vehicle on quadriceps protein expression using 
Western blot in high- and low-capacity runners (HCR, LCR).  
Quadriceps 
Main effects 
Interaction 
t-test for MTII≠vehicle 
MTII/vehicle HCR/LCR HCR LCR 
β2-AR 
F 0.633 7.983 0.027 
  
df 1,10 1,10 1,10 
  
p 0.445 0.018 0.872 0.275 0.327 
UCP2 
F 0.494 23.761 0.118 
  
df 1,10 1,10 1,10 
  
p 0.498 0.001 0.739 0.251 0.402 
UCP3 
F 0.766 24.987 0.263 
  
df 1,10 1,10 1,10 
  
p 0.402 0.001 0.619 0.198 0.398 
PPARα 
F 0.731 6.775 0.078 
  
df 1,10 1,10 1,10 
  
p 0.413 0.026 0.785 0.245 0.338 
PPARδ 
F 0.02 6.22 0.066 
  
df 1,10 1,10 1,10 
  
p 0.89 0.032 0.802 0.401 0.467 
PPARγ 
F 1.151 10.182 0.303 
  
df 1,10 1,10 1,10 
  
p 0.173 0.01 0.594 0.126 0.249 
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A
ut
ho
r M
an
us
cr
ip
t
PGC1α 
F 2.279 30.836 0.196 
  
df 1,10 1,10 1,10 
  
p 0.162 <0.001 0.667 0.109 0.246 
SERCA1 
F 3.919 19.141 0.397 
  
df 1,10 1,10 1,10 
  
p 0.076 0.001 0.543 0.047 0.212 
SERCA2 
F 2.538 20.539 0.13 
  
df 1,10 1,10 1,10 
  
p 0.142 0.001 0.726 0.116 0.208 
Kir6.1 
F 0.118 3.612 0.01 
  
df 1,10 1,10 1,10 
  
p 0.739 0.087 0.923 0.418 0.400 
Kir6.2 
F 0.405 24.289 0.000 
  
df 1,10 1,10 1,10 
  
p 0.539 0.001 0.985 0.336 0.335 
MED1 
F 0.216 32.532 0.024 
  
df 1,10 1,10 1,10 
  
p 0.652 <0.001 0.881 0.415 0.344 
ACC 
F 0.162 0.877 0.020 
  
df 1,10 1,10 1,10 
  
p 0.695 0.731 0.890 0.435 0.346 
pACC 
F 3.077 5.656 0.330 
  
df 1,10 1,10 1,10 
  
p 0.110 0.039 0.578 0.081 0.220 
AMPK 
F 0.010 0.000 0.000 
  
df 1,10 1,10 1,10 
  
p 0.923 0.991 0.995 0.472 0.474 
pAMPK 
F 6.679 20.554 0.300 
  
df 1,10 1,10 1,10 
  
p 0.027 0.001 0.596 0.041 0.101 
CD36 (FAT) 
F 0.081 6.323 0.039 
  
df 1,10 1,10 1,10 
  
p 0.782 0.031 0.847 0.369 0.477 
FAS 
F 0.002 0.002 0.024 
  
df 1,10 1,10 1,10 
  
p 0.966 0.964 0.880 0.452 0.466 
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